Related Experiment Video
Updated: Jul 4, 2025
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion
1odimm inc., Los Angeles, CA, United States.
Insights
Newborn screening for Pompe disease (PD) in over 11.6 million infants reveals a birth prevalence of 1:18,711. This large-scale study provides a reliable estimate for this rare genetic disease across diverse populations.
Area of Science:
- Genetics
- Newborn Screening
- Rare Diseases
Background:
- Pompe disease (PD) is a rare genetic disorder.
- Accurate prevalence data is crucial for public health initiatives.
- Previous estimates of PD prevalence have varied.
Purpose of the Study:
- To establish a precise birth prevalence figure for Pompe disease using the largest dataset to date.
- To compare different methodologies for estimating rare genetic disease frequencies.
- To provide a framework for assessing the reliability of prevalence data for rare diseases.
Main Methods:
- Analysis of over 11.6 million newborn screening (NBS) results for Pompe disease from 29 international programs.
- Direct detection of disease and binomial analysis.
- Comparison with Hardy-Weinberg equilibrium and confidence interval analyses.
Main Results:
- The birth prevalence of Pompe disease is determined to be 1:18,711.
- No significant differences in prevalence were observed across European, Latin American, or Asian populations.
- The study highlights the impact of sample size on the reliability of rare disease frequency estimates.
Conclusions:
- This study provides the most robust birth prevalence estimate for Pompe disease to date.
- The findings underscore the importance of large sample sizes in accurately determining the frequency of rare genetic disorders.
- A framework is proposed for evaluating and comparing frequency data across different rare diseases.
Abstract:
This study includes over 11.6M newborns screened (NBS) for Pompe Disease (PD) from 29 distinct universal screening programs across 8 countries and 4 continents. The birth prevalence of PD is 1:18,711, with no evidence of difference across populations of European, Latin American, or Asian ancestry, though differences may exist for PD subtypes. This study also compares these results, based on direct detection of disease and analyzed using a binomial method along with power analysis, with other methods for estimating the 'frequency' of rare genetic diseases (such as utilizing Hardy-Weinberg equilibrium on allele frequency and confidence interval analysis). This comparison demonstrates the implications of sample size and frames a discussion on its influence on the reliability of results when extrapolating to a population beyond the study dataset.
Objectives:
Primary: Establish a new figure for prevalence at birth for Pompe disease by collecting and analyzing the largest relevant dataset to date and using that result to project population prevalence at birth in a novel way. Secondary: Compare these results to previous analyses to offer a framework for evaluating 'frequency' data that can be applied to other rare, genetic diseases, along with methods to assess quality of estimates.
